Anticoagulant Therapy Guidelines

Introduction to Anticoagulant Therapy

• The American College of Cardiology, American College of Chest Physicians, and American Society of Clinical Oncology recommend the duration of anticoagulant therapy after surgery to be at least 7-10 days for most patients, with extension to 4 weeks (28 days) for high-risk patients undergoing major abdominal or pelvic cancer surgery, based on moderate to high strength of evidence 1

Patient-Specific Risk Factors

• Major cancer surgery, especially abdominal/pelvic, restricted mobility post-surgery, obesity, and history of previous VTE are significant risk factors for VTE, as identified by the National Comprehensive Cancer Network, American College of Physicians, American Heart Association, and American College of Cardiology 1
• Multiple risk factors for thrombosis increase the risk of VTE, as highlighted by the International Society on Thrombosis and Haemostasis 1

Procedure-Specific Risk Factors

• Most general and abdominal-pelvic surgeries without high-risk features require standard duration of anticoagulant therapy, while procedures with Caprini score 3-4 require extended duration of anticoagulant therapy, as recommended by the Society of Surgical Oncology and American College of Surgeons 1

Management of Anticoagulation

• For patients who develop post-operative atrial fibrillation, the American Heart Association recommends continuing anticoagulation for 30 days after return to normal sinus rhythm, based on high strength of evidence 2
• For patients with mechanical heart valves requiring surgery, the American College of Cardiology recommends continuing VKA anticoagulation with therapeutic INR for minor procedures, and bridging therapy with heparin for high-risk patients 3
• Therapeutic-dose LMWH should be resumed 48-72 hours after high-bleeding-risk surgery and 24 hours after non-high-bleeding-risk surgery, with timing contingent on surgical site hemostasis, as recommended by the American College of Chest Physicians 4
• The following table outlines the recommended timing for resuming DOACs post-surgery:

*Consider reduced dose (110-150mg once daily) on the evening after surgery and day 1 post-op for high thromboembolism risk patients, and consider reduced dose (rivaroxaban 10mg once daily or apixaban 2.5mg twice daily) for high thromboembolism risk patients, as per guidelines from Blood 5

Potential Complications

• Inadequate duration of prophylaxis can increase VTE risk, particularly for high-risk patients, as warned by the American College of Chest Physicians 1
• One-size-fits-all approach to anticoagulant therapy can lead to inadequate protection against VTE or excessive bleeding risk, as cautioned by the International Society on Thrombosis and Haemostasis 1
• Overlapping anticoagulants (e.g., administering heparin and DOACs simultaneously) increases bleeding risk without additional benefit, emphasizing the importance of careful anticoagulant management 6
• Standard prophylactic regimen: Once-daily dosing for at least 7-10 days postoperatively, with extension to 4 weeks for high-risk patients undergoing major abdominal or pelvic surgery, as suggested by guidelines from The Lancet Oncology 7
• For patients on therapeutic anticoagulation, monitor for signs of bleeding, including checking surgical site every 30 minutes initially and monitoring vital signs regularly, as recommended by clinical guidelines 6